#United States #Dublin #Financial Growth #Cardinal Health #FY2027 Guidance

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results

Overview

Cardinal Health (NYSE: CAH) has revealed its financial results for the fourth quarter and the full fiscal year 2026, showcasing a robust increase in revenue and earnings per share (EPS). The generated revenue for the fourth quarter reached $63.7 billion, marking a 6% growth compared to the previous year, while the diluted EPS saw a significant increase of 70% to $1.70.

Financial Summary

Fourth Quarter 2026 Performance

• - Revenue: $63.7 billion (up 6% from FY2025)
• - GAAP Diluted EPS: $1.70 (up 70%)
• - Non-GAAP Diluted EPS: $2.91 (up 40%), excluding a one-time impact from an IEEPA tariff refund
• - Operating Earnings: $729 million (up 70%)
• - Non-GAAP Earnings: $682 million (up 36%)

The reported numbers indicate a thriving operational performance, particularly in the Pharmaceutical and Specialty Solutions segment, which drove substantial growth due to brand and specialty pharmaceutical sales.

Fiscal Year 2026 Results

For the total fiscal year 2026, Cardinal Health reported revenues amounting to $254.2 billion, demonstrating a 14% growth from the prior fiscal year. The GAAP diluted EPS stood at $7.23, reflecting a 12% increase, whereas non-GAAP diluted EPS increased to $11.26, a notable 37% rise.

Segment Highlights

1. Pharmaceutical and Specialty Solutions Segment
- Revenue: $58.8 billion (6% increase)
- Segment Profit: $645 million (21% increase)
- This growth was largely driven by ongoing strong performance in existing brand prescriptions.

2. Global Medical Products and Distribution Segment
- Revenue: $3.1 billion (2% decrease)
- Segment Profit: $150 million
- The slight revenue decline was impacted by reduced distribution volumes, yet the segment profit expanded due to tariff refunds.

3. Other Segments (Nuclear and Precision Health Solutions, OptiFreight Logistics, etc.)
- Revenue increased by 7% with a profit of $183 million, attributed to growth across multiple services.

Strategic Developments

Cardinal Health’s management highlighted successful execution in operational strategies and investments in growth areas as pivotal to the strong yearly performance. CEO Jason Hollar remarked on the year’s broad operational strength, noting double-digit profit growth across all five operating segments, boosting confidence heading into fiscal year 2027.

Outlook for Fiscal Year 2027

Looking forward, Cardinal Health has provided optimistic guidance for FY2027, expecting non-GAAP diluted EPS to grow by 13% to 15%, projecting a range of $12.40 to $12.60. The growth forecast signals sustained confidence in operational momentum alongside strategic acquisitions, including a completed tuck-in acquisition of Strive Medical and an announced acquisition of AdaptHealth’s Diabetes Health business.

Shareholder Value Creation

The company is also committed to returning value to shareholders, having completed $1.4 billion in share repurchases within the year and receiving board approval for an increased share repurchase authorization of $5.0 billion. Additionally, Cardinal Health declared a quarterly dividend of $0.5158 per share payable in October 2026, emphasizing its dedication to shareholder returns.

Conclusion

In conclusion, Cardinal Health’s significant year-on-year growth in both revenue and EPS, combined with strategic projects and shareholder distributions, highlights its ongoing commitment to enhancing shareholder value and operational excellence. With a positive outlook for FY2027, Cardinal Health remains a critical player in the pharmaceutical and healthcare distribution landscape.